What are the storage conditions and methods of elacestrant tablets?

Elacestrant is a new oral selective estrogen receptor degrader (SERD), mainly used to treat estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer with ESR1 mutations. As the drug is gradually used in overseas markets, the rationality of its storage conditions is of great significance in ensuring the stability and efficacy of the drug. According to the instructions for the original drug Orserdu, the drug is currently on the market in tablet form, and the common dosage forms are 345 mg (equivalent to 400 mg Elacestrant hydrochloride) and 86 mg (equivalent to 100 mg Elacestrant hydrochloride).

The recommended storage conditions for elastran tablets are room temperature, 20°C to 25°C (68°F to 77°F). This temperature range is considered to be the most beneficial to maintaining the chemical stability of pharmaceutical products under standard storage conditions. In addition, drug labels also allow for slight temperature excursions within a short period of time. The acceptable variation range is 15°C to 30°C (59°F to 86°F), which means that small temperature fluctuations during transportation or patient storage will not significantly affect the quality of the drug.

The storage environment should avoid adverse factors such as direct sunlight, high temperature or humidity, as these physical conditions may accelerate the degradation of active ingredients and lead to a decrease in efficacy. In a home environment, elastran tablets should be placed in a dry, cool place and should be kept away from bathrooms, kitchens, or any humid spaces. In addition, the original packaging of the medicine should be kept intact and the containers should not be changed without authorization to ensure the moisture-proof function and complete label information.

In short, as an oral anti-cancer drug, the storage management of elastran should be carried out strictly in accordance with the instructions. Reasonable environmental control can help maintain the efficacy of the drug and reduce the risk of adverse reactions.

References:https://www.drugs.com/mtm/elacestrant.html